national
Moderna and Merck Report Positive Trial Results for Personalized Melanoma mRNA Vaccine
Just the facts
Pharmaceutical companies Moderna and Merck announced clinical results demonstrating that their experimental mRNA vaccine reduced the risk of recurrence or death in high-risk melanoma patients. The personalized vaccine utilizes artificial intelligence technology to tailor treatment based on unique genetic mutations identified in an individual patient's tumor tissue. Medical researchers reported that the trial outcome represents a milestone in expanding mRNA vaccine applications to oncology. Moderna shares experienced an upward movement on financial exchanges following the announcement of the trial data.
Why this is news
Moderna and Merck released clinical trial data evaluating a personalized mRNA cancer vaccine administered in combination with immunotherapy for high-risk melanoma patients.
Sources
This summary is compiled strictly from the original reporting below.